Dr. Tommy Wood on Tim Ferriss: The Lifestyle Levers That May Lower Dementia Risk, and What They Mean for APOE4 Carriers

This is our independent, journal-club style summary of Tim Ferriss’s conversation with Dr. Tommy Wood. We distill what was said and separate established evidence from where Wood is extrapolating. You can check everything below against the show’s official transcript.

Who is talking, and why it matters to you

Tommy Wood is an associate professor of pediatrics and neuroscience at the University of Washington, where his research covers brain health across the lifespan, including the treatment of adult brain trauma and the factors behind long-term cognitive decline. A few roles are worth keeping in mind as you read: he helped found the British Society of Lifestyle Medicine, he is head of research for the dementia-prevention charity Food for the Brain, and he is chief science officer for the brain-health coaching company BetterBrain. He has a new book, The Stimulated Mind. None of that makes him wrong. It does mean some of the framing is downstream of work he sells.

The whole episode is about lowering dementia risk through lifestyle. For an APOE4 carrier, the core question is always the same: does the genotype lock in my fate, or is there room to move? The conversation lands firmly on “there is room to move,” and Wood is reasonably careful not to overpromise.

The most carrier-relevant ideas, with the numbers in context

Genes load the gun, but a lot of dementia risk is modifiable. This was a central thread. The grounding is solid. The 45 percent figure comes from the most recent Lancet Commission on Dementia Prevention, which looked at 14 modifiable risk factors: low education, hearing and vision loss, high LDL cholesterol, brain trauma, physical inactivity, diabetes, smoking, high blood pressure, obesity, excessive alcohol, social isolation, depression, and air pollution. The higher end of the range is softer. Other studies suggest that more than 70 percent of dementia may be preventable once you include risk factors the Lancet analysis left out. Read the 45 percent as the better-supported anchor and the 70 percent as a more speculative ceiling. One nuance for carriers: these are population-level fractions of risk, not a promise that any one person can erase 45 to 70 percent of their own risk, and the Lancet number does not isolate APOE4 carriers.

The Auguste Deter story, used to argue genes are not destiny. Wood opened with Alzheimer’s index patient. His read: he does not think she actually had Alzheimer’s as we now define it, because genetic studies of preserved sections of her brain showed none of the mutations that cause early-onset Alzheimer’s, and she wasn’t an APOE4 carrier; he believes she was 3-3. This is a historical curiosity and a rhetorical setup, not evidence about APOE4 carriers. Treat it as an interesting hypothesis about one patient, not data.

The “use it or lose it” brain-energy idea. Wood pushed back on the simple story that Alzheimer’s is just the brain failing to take up glucose. On an FDG PET scan, less glucose gets into the brain in people with Alzheimer’s, and traditionally that has been read as glucose being unable to get in, which is where the idea of “type 3 diabetes” and brain insulin resistance comes from. His alternative: part of the reason we see less glucose uptake may be that those brain regions are less active because we are not using them, and the brain, like muscle, seems demand-driven, so we should think about how to create energetic demand to keep uptake up. Be clear on tiers. The PET finding is established. The “your brain is bored, not broken” interpretation is Wood’s hypothesis, not settled science. He is explicit that it applies early; advanced dementia, he says, is too late.

Exercise, especially “open-skill” movement and dance. This was one of the more carrier-useful sections. Wood separates open-skill activities, where you constantly react to a changing environment, from closed-skill exercise like jogging or steady cycling. When studies compare activities with the same physical challenge but different cognitive challenge, he argues, the open-skill ones show greater benefits in brain structure and function. On dance specifically, note that he caught himself. When Tim teed it up as the single strongest activity for dementia prevention, Wood said “probably” he was overstepping, then clarified that across depression studies and studies randomizing people to different activities, dance seems to have the highest effect size, but that dance bundles several things, including learning steps, a social component, and a music component, which are probably part of the magic. So the honest version is this: dance looks good, the effect likely comes from bundling several brain-healthy things together, and “single strongest activity” was Tim’s phrasing, which Wood declined to fully endorse.

VO2 max training. Wood referenced a study of roughly three-times-a-week high-intensity training. He was candid about his memory on the specifics: he said the intervention period was either six or 12 months and couldn’t remember which, and Tim noted durable effects over a follow-up of about five years, which Wood agreed with. The takeaway is appealing, a bounded training block with lasting benefit, but the vagueness on the actual study parameters is your cue to treat the specifics as approximate until you see the citation.

Omega-3s and B vitamins work together, not alone. This is the most carrier-actionable mechanism, and it is reasonably well supported. The B vitamins involved in methylation affect homocysteine, which you can measure with a blood test, and inadequate status shows up as elevated homocysteine. The historical point is key: earlier trials gave people B vitamins or omega-3s alone and saw little effect, and the resolution is that the two are interdependent. The first study to find this was VITACOG, which randomized people with elevated homocysteine (above about 13 micromol/L, the testable number to bring to your doctor) to daily B12 (0.5 mg), folic acid (0.8 mg), and B6 (20 mg), slowing brain atrophy and cognitive decline, with the benefit only in participants who had adequate omega-3 status. Multiple later trials found the same dependency in both directions. One number to hold loosely: a meta-analysis suggested omega-3 intake and homocysteine each contributed more than 20 percent of modifiable dementia risk, though Wood himself thinks that is probably an overestimate. For dosing he framed targets rather than megadoses: roughly one to two grams a day on average, or two or three good servings of seafood a week, or a reasonable supplement, is probably enough to hit those levels. That self-correction, “probably an overestimate,” is the kind of honesty worth trusting.

Creatine. Wood is a fan and takes it himself, about 10 g/day, which is worth flagging is higher than the 3 to 5 g/day used in most studies. He framed it as low risk with plausible upside, noting creatine is probably more beneficial if you already have it on board, and that at least one trial in pediatric traumatic brain injury showed enhanced recovery. He recommends a high-quality monohydrate (Creapure) and points to a meta-analysis finding no excess GI side effects versus placebo with good product. For carriers, the honest read is “plausible, broadly safe, not proven for dementia prevention,” which is roughly how he presented it rather than as a sure thing.

Fair warning: pitches, conflicts, and where claims run ahead of the evidence

• Conflicts of interest. Wood is head of research for a dementia-prevention charity and chief science officer of a brain-health coaching company, and he was on the show partly to launch a book. The episode’s overall thesis, that lifestyle meaningfully moves dementia risk, is also the thesis he sells. He was generally measured, but keep the incentives in view, especially anywhere the framing feels more confident than the underlying trials.

• Sponsor noise is not science. The episode is wrapped in ads (Eight Sleep, AG1, and others), with a limited-time discount offer for listeners. These are paid placements, not Wood’s recommendations, and not evidence of anything.

• Where claims outrun the evidence. The “single strongest activity for dementia prevention” line was Tim’s, and Wood backed away from it. The “use it or lose it” model is a hypothesis, not established fact. The 70 percent preventable figure is softer than the 45 percent Lancet number. The VO2 max study details were recalled vaguely. The Auguste Deter argument is a historical anecdote, not carrier data. None of these belong under “established.”

• What is on firmer ground. The Lancet 45 percent modifiable-risk framework, the omega-3 by B-vitamin interaction (VITACOG and later trials), and the general value of cardiorespiratory fitness for brain health are the better-supported pieces. Even here, almost none of it is APOE4-specific, so be careful translating population findings straight to your genotype.

Bottom line for a carrier

The encouraging message, that you are not helpless against your genes, is broadly defensible. The most concrete lever discussed, testing homocysteine and getting omega-3 and B-vitamin status adequate together, has real trial support. Just keep the speakers separate from the studies, and the opinions separate from the established findings.

---

This is general information for education, not medical advice. It is our distillation of the conversation rather than the guest’s exact words. Please read the official transcript for yourself and talk to your doctor before changing anything about your health.